Please note – you will leave a website owned by MacroGenics, Inc.
MacroGenics is not responsible for any content on the third party website.
MGA012 is a humanized, proprietary anti-PD-1 monoclonal antibody being developed by MacroGenics. Marketed antibodies targeting PD-1 have shown clinical efficacy in the treatment of various tumors. These antibodies act as checkpoint inhibitors, releasing the “brakes” on the immune system that are often imposed by tumors as a means to evade immune detection. We plan to evaluate MGA012 as monotherapy as well as in combination with our other potential cancer therapeutics. MGA012 affords MacroGenics considerable development flexibility as well as potential commercial advantages as compared to using a third-party anti-PD-1 agent.
A Phase 1 study of MGA012 is currently ongoing. Upon reaching a recommended Phase 2 dose, development will advance into multiple expansion cohorts. We intend to leverage the potential power of combination immunotherapy treatments by coupling MGA012 with other assets from our pipeline of product candidates.
MacroGenics retains full worldwide rights to MGA012.